BRIEF--Adocia and Lilly announce positive results from Phase 1b study of Lispro U100

* Adocia and Lilly announce positive results from a Phase 1b study of repeated administration of ultra-rapid biochaperone Lispro U100 in people with type 2 diabetes Source text for Eikon: Further company coverage: (Gdynia Newsroom)